GMAB
Price
$23.20
Change
+$0.12 (+0.52%)
Updated
Nov 11 closing price
92 days until earnings call
TECH
Price
$74.69
Change
-$1.27 (-1.67%)
Updated
Nov 11 closing price
84 days until earnings call
Ad is loading...

GMAB vs TECH

Header iconGMAB vs TECH Comparison
Open Charts GMAB vs TECHBanner chart's image
Genmab A/S ADS
Price$23.20
Change+$0.12 (+0.52%)
Volume$1.65M
CapitalizationN/A
Bio-Techne
Price$74.69
Change-$1.27 (-1.67%)
Volume$628.52K
CapitalizationN/A
GMAB vs TECH Comparison Chart
Loading...
GMAB
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
TECH
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
GMAB vs. TECH commentary
Nov 12, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GMAB is a Hold and TECH is a StrongBuy.

COMPARISON
Comparison
Nov 12, 2024
Stock price -- (GMAB: $23.20 vs. TECH: $74.69)
Brand notoriety: GMAB and TECH are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GMAB: 145% vs. TECH: 75%
Market capitalization -- GMAB: $14.53B vs. TECH: $11.87B
GMAB [@Biotechnology] is valued at $14.53B. TECH’s [@Biotechnology] market capitalization is $11.87B. The market cap for tickers in the [@Biotechnology] industry ranges from $476.71B to $0. The average market capitalization across the [@Biotechnology] industry is $2.81B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GMAB’s FA Score shows that 0 FA rating(s) are green whileTECH’s FA Score has 2 green FA rating(s).

  • GMAB’s FA Score: 0 green, 5 red.
  • TECH’s FA Score: 2 green, 3 red.
According to our system of comparison, TECH is a better buy in the long-term than GMAB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GMAB’s TA Score shows that 5 TA indicator(s) are bullish while TECH’s TA Score has 6 bullish TA indicator(s).

  • GMAB’s TA Score: 5 bullish, 3 bearish.
  • TECH’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, both GMAB and TECH are a good buy in the short-term.

Price Growth

GMAB (@Biotechnology) experienced а +1.84% price change this week, while TECH (@Biotechnology) price change was -1.49% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.07%. For the same industry, the average monthly price growth was +12.75%, and the average quarterly price growth was +8.86%.

Reported Earning Dates

GMAB is expected to report earnings on Feb 12, 2025.

TECH is expected to report earnings on Feb 04, 2025.

Industries' Descriptions

@Biotechnology (+2.07% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GMAB($14.5B) has a higher market cap than TECH($11.9B). TECH has higher P/E ratio than GMAB: TECH (78.62) vs GMAB (22.32). TECH YTD gains are higher at: -2.783 vs. GMAB (-27.136). GMAB has higher annual earnings (EBITDA): 7.88B vs. TECH (301M). TECH has less debt than GMAB: TECH (420M) vs GMAB (1.02B). GMAB has higher revenues than TECH: GMAB (19B) vs TECH (1.17B).
GMABTECHGMAB / TECH
Capitalization14.5B11.9B122%
EBITDA7.88B301M2,619%
Gain YTD-27.136-2.783975%
P/E Ratio22.3278.6228%
Revenue19B1.17B1,621%
Total Cash15.7BN/A-
Total Debt1.02B420M243%
FUNDAMENTALS RATINGS
GMAB vs TECH: Fundamental Ratings
GMAB
TECH
OUTLOOK RATING
1..100
649
VALUATION
overvalued / fair valued / undervalued
1..100
68
Overvalued
3
Undervalued
PROFIT vs RISK RATING
1..100
8867
SMR RATING
1..100
5081
PRICE GROWTH RATING
1..100
7850
P/E GROWTH RATING
1..100
9114
SEASONALITY SCORE
1..100
5065

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECH's Valuation (3) in the Biotechnology industry is somewhat better than the same rating for GMAB (68) in the null industry. This means that TECH’s stock grew somewhat faster than GMAB’s over the last 12 months.

TECH's Profit vs Risk Rating (67) in the Biotechnology industry is in the same range as GMAB (88) in the null industry. This means that TECH’s stock grew similarly to GMAB’s over the last 12 months.

GMAB's SMR Rating (50) in the null industry is in the same range as TECH (81) in the Biotechnology industry. This means that GMAB’s stock grew similarly to TECH’s over the last 12 months.

TECH's Price Growth Rating (50) in the Biotechnology industry is in the same range as GMAB (78) in the null industry. This means that TECH’s stock grew similarly to GMAB’s over the last 12 months.

TECH's P/E Growth Rating (14) in the Biotechnology industry is significantly better than the same rating for GMAB (91) in the null industry. This means that TECH’s stock grew significantly faster than GMAB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GMABTECH
RSI
ODDS (%)
Bullish Trend 1 day ago
69%
Bullish Trend 1 day ago
86%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
65%
Bearish Trend 1 day ago
65%
Momentum
ODDS (%)
Bullish Trend 1 day ago
64%
Bullish Trend 1 day ago
67%
MACD
ODDS (%)
Bullish Trend 1 day ago
66%
Bullish Trend 1 day ago
74%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
65%
Bearish Trend 1 day ago
69%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
68%
Bullish Trend 1 day ago
65%
Advances
ODDS (%)
Bullish Trend 9 days ago
65%
Bullish Trend 8 days ago
69%
Declines
ODDS (%)
Bearish Trend 7 days ago
67%
Bearish Trend 1 day ago
72%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
63%
Bearish Trend 1 day ago
81%
Aroon
ODDS (%)
Bearish Trend 1 day ago
67%
Bearish Trend 1 day ago
67%
View a ticker or compare two or three
Ad is loading...
GMAB
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
TECH
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
LIT47.002.62
+5.90%
Global X Lithium & Battery Tech ETF
DRLL29.740.10
+0.34%
Strive U.S. Energy ETF
FCSH24.17N/A
N/A
Federated Hermes Short Duration Corp ETF
VEA50.23-0.02
-0.04%
Vanguard FTSE Developed Markets ETF
OILK42.59-1.01
-2.32%
ProShares K-1 Free Crude Oil ETF

GMAB and

Correlation & Price change

A.I.dvisor indicates that over the last year, GMAB has been loosely correlated with GNMSF. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if GMAB jumps, then GNMSF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GMAB
1D Price
Change %
GMAB100%
+0.52%
GNMSF - GMAB
58%
Loosely correlated
+2.78%
AXON - GMAB
47%
Loosely correlated
+2.15%
VIR - GMAB
41%
Loosely correlated
+2.81%
ATNM - GMAB
35%
Loosely correlated
+0.52%
VCYT - GMAB
35%
Loosely correlated
+6.58%
More

TECH and

Correlation & Price change

A.I.dvisor indicates that over the last year, TECH has been loosely correlated with AXON. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if TECH jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TECH
1D Price
Change %
TECH100%
-1.67%
AXON - TECH
61%
Loosely correlated
+2.15%
ADPT - TECH
52%
Loosely correlated
+11.51%
QSI - TECH
51%
Loosely correlated
+6.39%
NTLA - TECH
49%
Loosely correlated
+4.66%
EDIT - TECH
49%
Loosely correlated
+5.77%
More